Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deven Parmar

Showing results (31-40 of 31) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 31 results.
Clinical Breast Cancer|July 28, 2024
A Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (Pertuzumab Biosimilar) With Perjeta® in Patients With HER2-Positive Metastatic Breast CancerRushabh Kothari, Maulik Doshi, P K Chaithanya, et al.
Pageof 4

Showing results (31-40 of 31) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 31 results.
Clinical Breast Cancer|July 28, 2024
A Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (Pertuzumab Biosimilar) With Perjeta® in Patients With HER2-Positive Metastatic Breast CancerRushabh Kothari, Maulik Doshi, P K Chaithanya, et al.
Pageof 4